Nvelop, Chroma merger creates opportunity for targeted epigenome editors

The merging of Nvelop and Chroma into nChroma creates an opportunity for delivering epigenome editors to specific cell types.

Chroma Medicine Inc. officially launched in 2021 with $125 million in series A funding and has since raised a $135 million series B. Chroma is among a small but emerging set of companies looking to modify the epigenome, which holds the promise of precise control of gene expression, but without directly cutting or mutating DNA and the safety risks that come with those approaches...